| Metric / Factor | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D | 38/100 | Unprofitable (EPS −$5.41), negative revenue YoY (−9.29%), no earnings visibility, micro-cap volatility (β=1.69). Modest recovery from 52W lows (3.71→10.77) offset by structural headwinds. | 6–12M |
| SA Quality/Value Composite | D− | 32/100 | No P/E (unprofitable). Negative EPS growth. Revenue contraction YoY. No dividend. Valuation cannot be anchored to earnings; enterprise value $180M against shrinking top-line suggests distressed context. | 6–12M |
| Zacks Earnings Momentum | F | 15/100 | No forward P/E, no earnings date disclosed, no analyst consensus. EPS YoY growth unavailable. Negative historical EPS (−$5.41) implies losses. Zero momentum signal. | 3–6M |
| Institutional & Smart Money Flow | C− | 48/100 | 52W return of +27.18% suggests capitulation reversal or distressed-value positioning. No volume data available. Micro-cap likely exhibits low institutional ownership and high retail/speculative activity. | 1–3M |
| Growth Sustainability & Moat | D | 35/100 | Negative revenue growth (−9.29% YoY). Health Care sector position offers structural upside, but operative weakness dominates. No moat indicators visible (no target price, no forward guidance). | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 52/100 | 52W volatility (3.71–13.45) = 263% range. Micro-cap, unprofitable, illiquid (avg vol 0.16M shares). Price recovery from lows suggests oversold, but fundamental recovery path unclear. | 3–6M |
| Penalty Overlay (Disclosure & Governance Risk) | E | −15 pts | Data gaps: no earnings date, no profile2 secondary source, no target price consensus, no dividend clarity. Limited transparency typical of distressed micro-caps. Applies −15pt reduction to confidence. | 6–12M |
| CONFIDENCE SCORE | C | 54/100 | LIVE_DATA is complete for quote & core metrics. Earnings and forward guidance missing. Assessment is directionally sound but constrained by missing fundamental visibility. Recommend primary-source confirmation before any trade. | 6–12M |
| Volatility & Drawdown Risk | E | 22/100 | Beta 1.69 (69% above market). 52W range 263%. Micro-cap liquidity exacerbates swings. Recent −2.89% daily move typical. Expect 20–40% drawdowns in adverse sentiment. | 1–3M |
| Crowding Risk Flag | C+ | 58/100 | Micro-cap status ($180M market cap) limits institutional crowding. Likely retail/speculative base. 52W +27% return may attract weak-hands momentum buyers; risk of sharp reversal if sentiment shifts. | 1–3M |
American Well Corp (AMWL) operates in the Health Care sector, specifically in telehealth / digital health delivery infrastructure. Peer benchmarks would include Teladoc Health (TDOC), Livongo Health (acquired), and regional telehealth platforms. AMWL's −9.29% YoY revenue contraction stands in stark contrast to post-pandemic telehealth growth narratives; this suggests either market saturation, competitive displacement, or operational execution issues. The unprofitable profile (EPS −$5.41) places AMWL in the pre-breakeven category, typical of early-stage digital health but increasingly challenged as the sector matures and larger players (CVS, UnitedHealth) integrate telehealth natively. Without forward earnings guidance or analyst consensus, relative valuation against peers cannot be computed. The $180M market cap positions AMWL as a micro-cap, implying minimal analyst coverage and higher information asymmetry risk versus Nasdaq-100 digital health leaders.
AMWL Stock Analysis & Forecast
Is AMWL a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
AMWL Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, AMWL shows balanced risk-reward characteristics.
Should You Buy AMWL Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in AMWL.